Cargando…

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

PURPOSE: To evaluate the use of blood cell–free DNA (cfDNA) to identify emerging mechanisms of resistance to PARP inhibitors (PARPi) in high-grade serous ovarian cancer (HGSOC). EXPERIMENTAL DESIGN: We used targeted sequencing (TS) to analyze 78 longitudinal cfDNA samples collected from 30 patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lheureux, Stephanie, Prokopec, Stephenie D., Oldfield, Leslie E., Gonzalez-Ochoa, Eduardo, Bruce, Jeffrey P., Wong, Derek, Danesh, Arnavaz, Torti, Dax, Torchia, Jonathan, Fortuna, Alexander, Singh, Sharanjit, Irving, Matthew, Marsh, Kayla, Lam, Bernard, Speers, Vanessa, Yosifova, Aleksandra, Oaknin, Ana, Madariaga, Ainhoa, Dhani, Neesha C., Bowering, Valerie, Oza, Amit M., Pugh, Trevor J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Precision Medicine and Imaging
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502468/ https://www.ncbi.nlm.nih.gov/pubmed/37327320 http://dx.doi.org/10.1158/1078-0432.CCR-23-0797

Ejemplares similares

Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
por: Madariaga, Ainhoa, et al.
Publicado: (2020)

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations
por: Madariaga, Ainhoa, et al.
Publicado: (2019)

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
por: Mansouri, Anita, et al.
Publicado: (2021)

Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
por: Kim, Joseph W., et al.
Publicado: (2021)

Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
por: Leman, Raphaël, et al.
Publicado: (2023)

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
por: Lin, Z. Ping, et al.
Publicado: (2018)

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
por: Kim, Joseph W., et al.
Publicado: (2023)

Comment on evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy
por: Madariaga, Ainhoa, et al.
Publicado: (2021)

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
por: Madariaga, Ainhoa, et al.
Publicado: (2023)

Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma
por: Wong, Derek, et al.
Publicado: (2023)

Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention
por: Karakasis, Katherine, et al.
Publicado: (2016)

Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
por: Lee, Jung-Min, et al.
Publicado: (2022)

Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2‐Year Durable Response
por: Valiakhmetova, Andge, et al.
Publicado: (2019)

Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
por: Gopinathan, Ganga, et al.
Publicado: (2022)

Heterogeneous alteration of the ERBB3–MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient
por: Colombo, Ilaria, et al.
Publicado: (2019)

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series
por: Kasherman, Lawrence, et al.
Publicado: (2021)

Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
por: Marastoni, Stefano, et al.
Publicado: (2022)

Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
por: Brown, Nicholas, et al.
Publicado: (2016)

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
por: Zimmer, Alexandra S., et al.
Publicado: (2019)

4429 Powering precision medicine research with the efficient construction of large diverse cohorts
por: Petukhova, Lynn, et al.
Publicado: (2020)

4058 Enhanced efficiency of large-scale clinical proteomic studies: when less is more
por: Thomas, Stefani, et al.
Publicado: (2020)

4199 A pilot randomized controlled trial of precision care for smoking cessation in the Southern Community Cohort Study
por: Senft, Nicole, et al.
Publicado: (2020)

4513 European Ancestry as a Risk Factor for Atrial Fibrillation in Puerto Rican Hispanics
por: Gonzalez-Cordero, Ariel
Publicado: (2020)

4440 Enhanced radiation therapy using chlorin-e6 conjugated gold nanoparticles
por: Jenkins, Samir V, et al.
Publicado: (2020)

4089 Clinical Implementation of Monte Carlo Dose Calculation for Patient-Specific Radiotherapy Quality Assurance
por: Parenica, Holly Marie, et al.
Publicado: (2020)

4228 A latent class analysis of seriously ill adults with multiple chronic conditions receiving palliative care
por: Murali, Komal, et al.
Publicado: (2020)

4292 Epigenetic Age and Depressive Symptoms in African American Women with Cardiometabolic Conditions
por: Perez, Nicole B, et al.
Publicado: (2020)

4167 Peri-transplant Lung Microbiome Reveal Oral Bacteria, Pepsin And Inflammatory Markers Co-associate With Primary Graft Dysfunction, Implicating Aspiration As A Potential Contributor
por: McGinniss, John Evan, et al.
Publicado: (2020)

4043 Saliva microRNA for pediatric concussion assessment
por: Hicks, Steven, et al.
Publicado: (2020)

4565 Sex-Specific Differences in the Genomic Landscape of Pediatric and Adult Glioblastoma
por: Ivanov, Nikolay A., et al.
Publicado: (2020)

4106 Personalizing Care For Colorectal Cancer: Identifying Novel Opportunities
por: Rivers, Zachary, et al.
Publicado: (2020)

4482 Horizontal ridge augmentation in maxilla using bone expansion vs bone splitting techniques in adult patients: a prospective cohort
por: Acevedo, Amanda Figueroa, et al.
Publicado: (2020)

4518 Metabolomic Identifiers Predictive of Adverse Events due to Acetaminophen Administration
por: Sonn, Brandon Joseph, et al.
Publicado: (2020)

4360 Black Bone MRI from the Lab to Clinical Practice: Eliminating Radiation Exposure in Reconstructive Surgery Patients
por: Suchyta, Marissa, et al.
Publicado: (2020)

4023 Catecholamines and Opioid Therapy Requirements for the Management of Acute Post-Procedural Pain: The clinical Trend to Identify Remarkable Elements in Opioid Drug Dependency
por: Rivera, Armando Uribe, et al.
Publicado: (2020)

4061 Clinical utility of precision medicine approaches to guide anti-platelet selection for adult patients with acute coronary syndromes (ACS), following percutaneous coronary intervention (PCI)
por: Mosley, Scott, et al.
Publicado: (2020)

4385 The Pain and Social Experiences Project: Understanding the role of interpersonal trauma in pain
por: Pierce, Jennifer, et al.
Publicado: (2020)

4267 Noninvasive hybrid ultrasound and photoacoustic imaging for the assessment of liver fibrosis
por: Sultan, Laith Riyadh, et al.
Publicado: (2020)

4146 Establishment of Screening Methods for G6DP Deficiency – Translational and Clinical Applications
por: Gomez, Christian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v9uculm45gim0199v5k8oboiao